A Two-part Trial to Evaluate the Safety, Tolerability, Clinical Effect and Systemic Exposure Potential of Topically Applied GSK2981278 Ointment in Subjects With Plaque Psoriasis
Phase of Trial: Phase I/II
Latest Information Update: 20 Jul 2017
At a glance
- Drugs GSK 2981278 (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors GlaxoSmithKline
- 01 Jul 2017 Status changed from recruiting to completed.
- 31 Mar 2017 Planned End Date changed from 1 Dec 2017 to 13 Nov 2017.
- 31 Mar 2017 Planned primary completion date changed from 1 Dec 2017 to 13 Nov 2017.